FIG. 2.

Prediabetic NOD mice were treated with AS605240 for 7 weeks beginning at 10 weeks of age. A: Representative example of pancreatic histology from AS605240-treated group and untreated control at 20 weeks of age. Insulitis score at 20 weeks of age measured on 30 different islets from four mice per group is presented in B. IFN-γ ELISpot analysis (C) and Luminex assay on supernatant (D) from an ex vivo BDC2.5-pancreatic-peptide challenge of splenocytes recovered from AS605240-treated mice compared with control NOD mice at 20 weeks of age (*P < 0.05, n = 4 mice in each group). E: Flow cytometry analysis on splenocytes from treated mice at 20 weeks of age shows significant suppression of the absolute count of CD4 effector T cells (CD4⁺CD44^highCD62L^low) and CD8 effector T cells (CD8⁺CD44^highCD62L^low) while sparing Tregs (CD4⁺CD25⁺FoxP3⁺) compared with control (*P < 0.05; n = 4 mice in each group). F: Representative example of FACS staining from splenocytes of treated and control NOD mice at 20 weeks of age shows higher percentage of Tregs (CD4⁺CD25⁺FoxP3⁺) in treated compared with control mice. G: Bar graph shows the percentage of Tregs analyzed by flow cytometry in splenocytes of treated mice compared with control at 20 weeks of age (*P < 0.05; n = 4 mice in each group). Results are presented as the mean ± SEM. (A high-quality digital representation of this figure is available in the online issue.)